The deal RGS/Kyocera took longer than announced. RGS management might be cautious about saying too much re deals in the works. Their latest presentation was particularly light on this subject. However, if Kyocera's recent partnerships are any indication, especially in the stem cells area, they have also supported their research partners with expansion in Europe through their network. In other words, beyond the $27M upfront payments, the double digit royalties for incoming sales in Japan, the Kyocera partnership could accelerate RGS expansion in Europe, possibly in the US too. Most importantly, RGS was granted a US patent for Progenza in July 2018. Onwards and upwards.
RGS Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
